Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis

NCT01743651 is registered in ClinicalTrials.gov with RVL Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01743651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01743651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Lead sponsor
RVL Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2012
Completion date
April 30, 2014
Enrollment
353 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, spasticity